Key Facts
- Class: GLP-1R/amylin receptor agonists
- Proposed indication: Obesity
- Action: US FDA IND application submitted
- Efficacy: No human combination results reported
- Safety: No combination safety rates reported
- Status: Investigational; US submission
Ascletis also reported compatibility between the components, room-temperature stability, and a small tablet size. These formulation characteristics may be relevant to product development, but the release provides no patient adherence or treatment-persistence data. The animal pharmacokinetic findings do not establish once-daily exposure or an effective dose in humans.¹
For ASC39 alone, the company reported 40-fold selectivity for the human amylin 1 receptor over the human calcitonin receptor. In diet-induced obese rats, 6 consecutive days of once-daily oral administration produced a 6.6% placebo-adjusted body-weight reduction, compared with 5.6% for eloralintide. These are preclinical results, not estimates of weight loss patients can expect.¹
Human Evidence Remains Component-Specific
ASC30 is being evaluated in 2 global pivotal phase 3 trials, AURORA-1 and AURORA-2. According to Ascletis, the program is enrolling approximately 4600 participants with obesity or overweight across the US, Europe, and Canada. Topline results are expected in the third quarter of 2028. These studies concern ASC30, not the fixed-dose combination.¹
The company also cited a vomiting rate with ASC30 approximately half that reported for orforglipron when both drugs used weekly titration in separate studies. This non–head-to-head comparison cannot establish superior gastrointestinal tolerability. The announcement supplies no corresponding combination safety results, adverse-event rates, or discontinuation data. Ascletis separately reported submitting a US IND application for ASC39.¹
Clinical Questions and Next Steps
For clinicians, the principal question is whether combining these receptor targets in one oral tablet can deliver meaningful weight reduction with manageable adverse effects. The announcement does not establish the combination’s place relative to existing obesity treatments.¹
The reported regulatory action is an IND submission—not marketing approval. The release does not report FDA clearance to begin the combination study, a clinical trial protocol, planned enrollment, dosing, or endpoints. Human dose-finding, efficacy, and safety results will be necessary to assess the co-formulation; longer-term ASC30 findings will not independently resolve those questions.¹
References
- Ascletis Pharma Inc. Ascletis submits IND application to the U.S. FDA for ASC30_39 FDC, a potentially first-in-class oral small molecule fixed-dose combination of GLP-1R agonist and selective amylin receptor agonist, for the treatment of obesity. PR Newswire. November 11, 2026. https://www.prnewswire.com/news-releases/ascletis-submits-ind-application-to-the-us-fda-for-asc3039-fdc-a-potentially-first-in-class-oral-small-molecule-fixed-dose-combination-of-glp-1r-agonist-and-selective-amylin-receptor-agonist-for-the-treatment-of-obesity-302935882.html